Chartwell Partners is pleased to announce that Helen Kim has joined Prothena’s Board of Directors. Prothena Corporation plc is a public, late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Ms. Kim has over 27 years of experience in leadership roles in biotechnology, including her previous role as Executive Vice President of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives, leading to a successful acquisition by Gilead in 2017. Currently, Ms. Kim serves as a Senior Managing Director at Vida Ventures, LLC, a position which she has held since April 2019. Prior to her current role, Ms. Kim was a Partner at the Column Group from 2018-2019 and Executive Vice President, Business Development at Kite Pharma, Inc. from 2014-2018. Ms. Kim held positions as Chief Business Officer (2009-2012) and then Strategic Advisor (2012-2014) of NGM Biopharmaceuticals, Inc. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences where she restructured and repositioned the company prior to a successful transaction with Bristol Myers Squibb in 2008. Ms. Kim’s additional industry experience includes executive and leadership positions at Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc., and Chiron Corporation. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.